

PRINCIPLES OF ANTIBIOTIC USE

REBEKAH MOEHRING, MD, MPH; DUKE UNIVERSITY MEDICAL CENTER
MEDICAL DIRECTOR, ANTIMICROBIAL STEWARDSHIP AND EVALUATION TEAM
SPICE 2023

Disclosures

Grants to Institution: CDC, AHRQ

Royalties: UpToDate, Inc.

Acknowledgements:

John Juliano, MD (UNC)

Deverick Anderson, MD, MPH (Duke)

Robin Jump, MD (Pittsburg VAMC)

Objectives

Understand why antibiotics are “special” medications

The 4 Moments of Antibiotic Decision-Making

Antimicrobial Stewardship Programs

“Action” strategies in different clinical settings

We Love Antibiotics

Inpatient

At any given time, 62% of inpatients at DUMC are receiving at least one antimicrobial

There are >24,000 antimicrobial admissions at DUMC annually

DUMC spends >\$12 million on antimicrobial agents each year

Long-term Care

Up to 70% of residents in a nursing home receive one or more courses of systemic antibiotics when followed over a year

40-75% of antibiotic prescriptions are inappropriate

Outpatient

423-553 antibiotic prescriptions per 1000 people in the US per year

30% are unnecessary, (representing 47 million prescriptions/year)

Why We Love Antibiotics

Wonder Drug

Active intervention

Experiences

Tangible

Insurance



Antibiotics are time-tested
placebos

Antibiotic Rx is easy:

- Avoids doing a structured exam or long DDx
- Avoids time-consuming discussions
- i.e. Easier to treat than diagnose or educate

Identifying Infected vs. Not
Infected is hard

“Just in case” perceived to be
lower risk than “watchful waiting”

Why we **HAVE TO** improve Antibiotic Use

Antibiotics are unlike any other drug, in that the use of the agent in one patient can compromise its efficacy in another.

A lot of antibiotic prescriptions are unnecessary or sub-optimal.


We are running out of antibiotics.

Antibiotic misuse harms patients.

Improving antibiotic use has many benefits for patients and society.



Antimicrobial Use Impacts: Infection Prevention, HAIs, AND Patient Outcomes



Drug-resistance (MRSA, VRE, CRE, MDR-GNs)

C. difficile infection

Infection treatment success/failure

- Complications
- Readmissions
- Mortality
- Length of Stay

Adverse Safety Events

- Allergic reactions
- Drug toxicity events
- Acute Kidney Injury

Healthcare Resources and Cost

- (all of the above)
- Pharmacy budget; ICU days


One in Five Inpatients get an Antibiotic Adverse Drug Event

1488 patients followed for 30 days after antibiotic initiation

Followed 90 days for CDI and MDRO acquisition

General medical inpatients who had at least 24h of antibiotics during admission

20% of patients experienced at least one antibiotic-associated ADE



Tamma et al. JAMA Int Med. 2017 177(9):1308-15.

A case

86F with history of dementia, diabetes, and poor functional status presents from SNF with confusion, fever.

ED: Hypotense, non-verbal. Fluid resuscitated, cultures drawn, started on vancomycin + zosyn and admitted to the floor with diagnosis of sepsis.

Day 3: Remains on vancomycin and zosyn, progress note still says “sepsis.” BCx negative. Awake/interactive.

Urine culture: E. coli susceptible to multiple oral and intravenous agents.

Making the Right Decision Is Important


Getting the correct antibiotic to our sickest patients in a timely manner is critical.

Inappropriate empiric antibiotics associated with increased mortality and longer length of stay.

- In febrile inpatients, in ICU patients

In Septic Shock, each hour delay in administration of appropriate antimicrobials is associated with increased mortality.

- Average decrease in survival of 7.6%/hour over the first 6h after shock onset



+You Search Images Maps Play YouTube Gmail Drive More ▾



sepsis antibiotics



Web

Images

Videos

News

Shopping

Maps

Books

About 69,564,000 results (0,81 seconds)

Did you mean: **vanc/zosyn**

Created with didyoumean-generator.com



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

But, not for ALL infected patients

“Sepsis” without shock – a very heterogeneous population that does NOT show the same time-related associations with antibiotic/mortality

Sepsis can be hard to diagnose. Many patients with hypotension have non-infectious diagnoses.

- pulmonary emboli, fluid under/overload, toxin exposures, drug adverse effects, malignancies, bleeding, mechanical complications of surgery, obstructed organs, etc....

Overly tight limits on timing of antibiotics for suspected sepsis may cause clinicians to err on the side of over-treatment, skip diagnostic steps, and subject patients to the harms of antibiotic overuse.

Weinberger et al. J Infect Dis. 2020 Jul 21;222(Suppl 2):S110-S118

Liu VX. Am J Respir Crit Care Med 2017; 196:856–863

Seymour CW, et al. N Engl J Med 2017; 376:2235–2244

AU represents a modifiable risk

AU in Nursing Homes is highly variable and correlated with AEs

Figure. Variability of Antibiotic Use (per 1000 Resident-days) Across Ontario Nursing Homes





Table 3. Antibiotic-Related Adverse Outcomes Among Residents Living in Nursing Homes With Low, Medium, and High Antibiotic Use^a

Characteristic	Antibiotic Use, No. (%)		
	Low (n = 33 822)	Medium (n = 31 425)	High (n = 24 943)
<i>Clostridium difficile</i>	274 (0.8)	268 (0.9)	221 (0.9)
Diarrhea or gastroenteritis	3347 (9.9)	3388 (10.8)	2889 (11.6)
Infection with antibiotic-resistant organism	412 (1.2)	431 (1.4)	319 (1.3)
Antibiotic allergy	13 (0.0)	25 (0.1)	22 (0.1)
General adverse event from medication	96 (0.3)	124 (0.4)	88 (0.4)
Any antibiotic complication with or without potential for indirect harms to nonrecipients (primary composite outcome ^b)	3869 (11.4)	3890 (12.4)	3311 (13.3)
Only antibiotic complications with potential for indirect harms to nonrecipients (secondary composite outcome ^c)	3797 (11.2)	3801 (12.1)	3237 (13.0)

Acute Care Academic Hospitals



Polk et al. CID; 2011 Dec;53(11):1100-10



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

Good use of antibiotics requires balance. It's nuanced and complex.

Right Diagnosis

Right Drug


Right Dose

Right Timing

Right Duration

Improve therapeutic choices
(underuse)

Reduce unnecessary use
(overuse)



The “4 Moments” of Antibiotic Decision-Making

1

Does the patient have an infection that requires antibiotics?

2

Have I ordered appropriate cultures before starting antibiotics?

What empirical antibiotic therapy should I initiate?

3

A day or more has passed.

Can I stop antibiotics?
Can I narrow therapy?
Can I change from IV to oral therapy?






4

What duration of antibiotic therapy is needed for this patient's diagnosis?

5 or 6 “Ds” of Antimicrobial Stewardship

Goebel et al. Clin Micro Rev 2021.
<https://doi.org/10.1128/CMR.00003-20>

Morency-Potvin, Schwartz, Weinstein. Clin Micro Rev 30: 381-407	
Diagnosis	Make and document the right diagnosis.
Debridement/ Drainage	Drainage of abscesses and removal of necrotic tissue or foreign material when required.
Drug	Use the right drug empirically according to suspected or confirmed diagnosis, risk factors for resistant pathogens, allergy, or major side effects.
Dose	Use right dose according to diagnosis, site of infection, or renal/hepatic dysfunction.
Duration	Use drugs for an appropriate duration.
De-escalation	Re-evaluate diagnosis and therapy routinely and de-escalate therapy to narrow-spectrum and/or oral agents when appropriate.

 Diagnosis	Make and document the right diagnosis
 Drug	Use the right empiric antibiotic
 Dose	Use the right dose of antibiotic based on site of infection and renal or hepatic dysfunction
 Duration	Use antibiotics for the recommended duration
 De-escalation	De-escalate therapy based on susceptibilities and when urine cultures are negative

Clinical information: Small pieces over time.

Clinical information trickles in over time.

This means clinicians have to reassess regularly.

This also means they get interrupted with 'real-time' notifications and need to respond.

This a complex process: unpredictable, unknowns, uncertainty.

Putting the puzzle together completely takes attention, follow up on details, ability to make decisions in the setting of unknowns, AND an eye on the long-term goals.



General Indications for Antibiotics

Prophylaxis: prevent infection


- EASY! Guidelines and ordersets

Empiric: when you suspect infection but don't exactly know with what pathogen

- Not easy. Local guidelines help (based on local micro data).

Directed: pathogen known

- Moderately easy. Follow and interpret patient-specific micro data.



Choice of Empiric Antimicrobials: Clinical Syndrome

What class of pathogen am I likely to be treating?

- (Bacterial? Viral? Fungal? Other?)

If bacterial, what organisms are most likely?

- (Gram positive? Gram negative? Anaerobe?)

What information can I get to guide treatment?

- Microbiology data?

Do I need to order any other diagnostic tests?

How sick is my patient? How risky would it be if I miss?

Is my patient “special”? – allergy, ADEs, immune status

2

Have I ordered appropriate cultures before starting antibiotics?


What empirical antibiotic therapy should I initiate?

Traditional Microbiologic Culture

- “Gold standard” for diagnosis
- Requires sampling of site of infection *prior to* therapy
- Allows determination of phenotypic antimicrobial susceptibility



Growth? Up to 5 days



DIAGNOSIS: Stain

Direct Visualization


Gram stain

- Often provide clues to etiology (may allow presumptive diagnosis in some cases)
- Gram Positive
- Gram Negative
- Non-staining

Shape

- Cocci
- Rods

Aerobic/Anaerobic



Quick and Dirty Anti-bacterial Classification

Gram positive – skin, lung, guts, devices

Gram negative – guts, urine, some lung, chronic wounds

Atypicals – lung, STIs


Anaerobes –gas- and abscess-forming, bad odors

Fungi – guts, devices, immunosuppressed + abx-exposed hosts

GRAM POSITIVE ORGANISMS

Gram positive cocci


- *Staphylococcus aureus*
- Coagulase negative staphylococcus
- *Streptococcus pneumoniae*
- *Streptococcus* sp.
- *Enterococcus* sp.



Gram positive – skin, lung, guts, devices

Gram positive rods

- *Bacillus* sp. (aerobes)
- *Clostridium* sp. (anaerobes)



MSSA:
Cefazolin
Nafcillin/Oxacillin

MRSA:
Vancomycin
Daptomycin
TMP/SMX
Linezolid

Strep:
Penicillin
Ampicillin/Amoxicillin

Ceftriaxone


Enterococci: Ampicillin,
Vancomycin

VRE: Daptomycin, Linezolid

GRAM NEGATIVE ORGANISMS

Gram negative cocci

- *Neisseria meningitidis*
- *Neisseria gonorrhoeae*




Gram negative rods (enteric)

- *E. coli*
- *Klebsiella* sp.
- *Enterobacter* sp.
- *Proteus* sp.
- *Serratia* sp.

Gram negative rods (non-enteric, non-lactose fermenters)

- *Pseudomonas aeruginosa*
- *Stenotrophomonas maltophilia*
- *Acinetobacter* sp.




CA-Enterics:
Ceftriaxone
Quinolones
TMP/SMX

Gram- negative: guts, urine, some lung

Anti-pseudomonal or HA-Resistant Enterics:
Pip/tazo
Cefepime
Ceftazidime
(Carbapenem)

Antibiotics with Anti-anaerobic Activity



Class	Agents (Route)	<i>B. fragilis</i> susceptibility ⁴⁻⁷
Beta-lactam beta-lactamase inhibitor combinations	amoxicillin/clav (PO)	90-97%
	ampicillin/sulb (IV)	97%
	piperacillin/tazo (IV)	> 99%
Cephalosporin	cefotetan (IV)	N/A
	cefoxitin (IV)	83-90%
Carbapenem	doripenem (IV)	> 99%
	ertapenem (IV/IM)	
	meropenem (IV)	
	imipenem (IV)	
Fluoroquinolone	moxifloxacin (IV/PO)	66-70%
Other	clindamycin (IV/PO)	66-70%
	metronidazole (IV/PO)	> 99%
	tigecycline (IV)	81-96%

B. fragilis is the most common group of gut anaerobes.

Then GPRs (*Clostridium* spp.)

Also consider: mouth, vaginal sources

Gas- and abscess-forming, bad odors

C. difficile is a special case (oral vancomycin).

NON-STAINING Bacterial PATHOGENS

- “Atypicals” -- Not stained by Gram’s method (Intracellular)
 - *Legionella* sp. (Antigen test of the urine)
 - *Chlamydia* (PCR)
 - *Rickettsia* (Serology or PCR)

- Mycobacteria
 - *M. tuberculosis*
 - Non-tuberculous mycobacteria



Ziehl-Neelsen Stain of TB

Macrolides:
Azithromycin
Clarithromycin

Tetracyclines:
Doxycycline
Minocycline

Community-acquired pneumonia	Pathogens	CXR pattern
Typical pneumonia	Bacterial: <i>S. Pneumoniae</i> <i>H. Influenzae</i>	Lobar, dense
Atypical pneumonia	Viral: influenza, RSV Bacterial: <i>Legionella</i> <i>Mycoplasma</i> <i>Chlamydia</i>	Diffuse, patchy

Fungi

Candida/Yeast

- Fluconazole
- Echinocandins (micafungin, caspofungin)


Cryptococcus

- Amphoteroicin + flucytosine
- Fluconazole

Molds (Rhizopus/Mucor, Aspergillus)

- Voriconazole
- Posaconazole, Isavuconazole
- Itraconazole

<http://drfungus.org>



Guts, devices,
immunosuppressed
+ abx-exposed
hosts



Duke Center for
Antimicrobial Stewardship
and Infection Prevention


DIAGNOSIS: Antigen Tests

- Very useful for following (and sometimes diagnosing) viral infections: HIV, HBV, COVID-19
- Occasionally useful for other pathogens (e.g., Cryptococcus)
- Quick/rapid tests are often based on antigen testing, less expensive
- Urine is sometimes used for antigen tests (e.g. Legionella urine antigen)
- Limitations: Less Sensitivity



DIAGNOSIS: Serology or Antibody Tests

- For bacterial infections, generally not useful in early diagnosis (usually requires acute and convalescent tests)
- For viral infections, IgM may allow early diagnosis (e.g., HepA)
- Works ok for difficult to access/culture pathogens
- Limitation: slower turnaround, cannot distinguish phase of illness
 - E.g. Syphilis IgG -- after initial infection, test remains positive for lifetime



DIAGNOSIS: PCR and Molecular tests



- Highly sensitive
- Allows diagnosis of non-culturable pathogens (e.g., norovirus)
- Limitations: Subject to false positives (e.g. *C. difficile* colonization vs. infection?)
- Rapid turnaround time
- Increasing use of Syndromic Panel tests (e.g. blood, respiratory, CSF, GI) that also include resistance genes
- E.g. Blood culture + GNR – get pathogen ID and molecular resistance gene targets within 1-2 hours



Pathogens are tricky.

Antibiotic = A drug that kills or inhibits the growth of bacterial pathogens

Resistant = Designation that implies that an antimicrobial will not inhibit bacterial growth at clinically achievable concentrations

Susceptible = Designation that implies that an antimicrobial will inhibit bacterial growth at clinically achievable concentrations

Susceptibility

	Serratia marcescens MIC
Amikacin	S
Ampicillin	R
Ampicillin + Sulbactam	R
Cefazolin	R
Ceftriaxone	S
Ciprofloxacin	I
Gentamicin	S
Piperacillin/Tazobactam	S
Tobramycin	S
Trimethoprim + Sulfamethoxazole	S




MIC = Minimal inhibitory concentration. Lowest concentration of antimicrobial that inhibits growth of bacteria. Commonly used in clinical lab

Breakpoint = The MIC that is used to designate between susceptible and resistant.


Intrinsic vs. Acquired

Known quantity of bacteria placed into each tube



Increasing antibiotic concentration

Mechanisms of Action of Antibiotics



Patients are individuals.

Drug interactions

Age

Allergies

Pregnancy, breast feeding

Toxicity (idiosyncratic reactions)


Dose adjustment for renal and/or hepatic dysfunction

Ability to absorb an oral antibiotic

Immune status

Adherence:

- Cost
- Taste
- Frequency of administration
- Pill size
- Duration of therapy
- Multiple drug therapy
- Adverse effects
- Current symptoms



De-escalation


De-escalation is a core principle of Antimicrobial Stewardship.

Target/narrow antibiotic therapies after more clinical data returns


Stop therapy when infection has been ruled out

Goal: Reduce selective pressure, improve safety

Empiric
Broad-spectrum



Targeted
Narrow-spectrum



Durations (OLD)

- Most guideline-recommended antibiotic durations are based on...
- Qualified with “it depends...”
- Duration questions are ~70% of ID consults.

The answer, Dr. Gilbert, is that this is highly-specialized knowledge, rarefied information that only 100% Board-Certified, USDA-inspected Infectious Diseases Doctors know. And since I'm concerned that your article might give readers the wrong impression about our scientific credibility, I'll now divulge what we've learned, and how to apply it.

To figure out how long antibiotics need to be given, use the following rules:

1. Choose a multiple of 5 (fingers of the hand) or 7 (days of the week).
2. Is it an outpatient problem that is relatively mild? If so, choose something less than 10 days. After application of our multiples rule, this should be 5 or 7 days.
3. Is it *really* mild, so much so that antibiotics probably aren't needed at all but clinician or patient are insistent? Break the 5/7 rule and go with 3 days. Ditto uncomplicated cystitis in young women.
4. Is it a serious problem that occurs in the hospital or could end up leading to hospitalization? With the exception of community-acquired pneumonia (5 or 7 days), 10 days is the minimum.
5. Patient not doing better at the end of some course of therapy? Extend treatment, again using a multiple of 5 or 7 days.
6. Does the infection involve a bone or a heart valve? Four weeks (28 days) at least, often 6 weeks (42 days). Note that 5 weeks (35 days) is not an option — here the 5's and 7's cancel each other out, and chaos ensues.
7. The following lengths of therapy are inherently weird, and should generally be avoided: 2, 4, 6, 8, 9, 11, 12, 13 days. Also, 3.14159265 days.

In this highly data-driven exercise, it is important also to note the *number* of rules — *seven*, as in days of the week.

<https://blogs.jwatch.org/hiv-id-observations/index.php/how-to-figure-out-the-length-of-antibiotic-therapy/2010/10/22/>



NEW: Trials comparing short- vs. longer-course antibiotics have shown short-course is just as effective

Disease	Antibiotic Duration	
	Short	Long
Community-acquired pneumonia	3-5 days	7-10 days
Nosocomial pneumonia (HAP/VAP)	≤ 8 days	10-15 days
Pyelonephritis	5-7 days	10-14 days
Intraabdominal infection	4 days	10 days
Acute exacerbation of chronic bronchitis (AECB) and COPD	≤ 5 days	≥ 7 days
Acute bacterial sinusitis	5 days	10 days
Cellulitis	5-6 days	10 days
Chronic osteomyelitis	42 days	84 days

5 is the new 7

WHAT IS ANTIMICROBIAL STEWARDSHIP?



IDSA/SHEA/PIDS definition

“coordinated interventions designed to improve and measure the appropriate use of [antibiotic] agents by promoting the selection of the optimal [antibiotic] drug regimen including dosing, duration of therapy, and route of administration.”

-- Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), and the Pediatric Infectious Diseases Society (PIDS)

Barlam et al. *CID* 2016; 62(10): e51-77.
Fishman et al. *ICHE* 2012; 33:322-7.

Antimicrobial Stewardship Program

Decision support for prescribers of antimicrobials.

Coordinated program


Multidisciplinary teams

- MD, PharmD, RN, micro, IP, IT

Multi-level interventions:

- Educational
- Systems-based vs. 1:1
- Technology
- Active vs. Passive

I got your back, man.



Goals of Antimicrobial Stewardship

Primary:

- Improve quality and increase safety through appropriate use of antimicrobials
 - Improve therapeutic choices (underuse)
 - Reduce unnecessary use (overuse)

Secondary:


- Decrease emergence of resistance

Desirable “side effects” from an ASP:

- Decrease costs for health system
- Satisfy regulatory requirements (2017)

The goal is NOT to
decrease antibiotic use...

It's to IMPROVE antibiotic use!



Resources for Inpatient Stewardship

IDSA/SHEA guidelines on Implementing an ASP (2009, 2016): *CID* 2016;62(10):e51–e77

CDC Core Elements Document(s) (2014, 2019, 2022 “priorities”): <https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf>

The Joint Commission Standard (2017, 2022): <https://www.jointcommission.org/resources/patient-safety-topics/infection-prevention-and-control/antibiotic-stewardship>


CMS Condition of Participation (2020): Federal Register 9/30/2019

Clinical Infectious Diseases
IDSA GUIDELINE



Implementing an Antibiotic Stewardship Program:
Guidelines by the Infectious Diseases Society of America
and the Society for Healthcare Epidemiology of America

Tamar F. Barlan,^{1,2} Sara E. Cosgrove,^{2,3} Lilian M. Abbo,⁴ Conan MacDougall,¹ Audrey N. Schaez,⁵ Edward J. Septimus,⁶ Arjan Sriwastava,⁷ Timothy H. Dellit,⁸
Yogya T. Fatck-Yitir,⁹ Neil D. Fishman,¹⁰ Cindy W. Hamilton,¹¹ Timothy C. Jenkins,⁶ Pamela A. Lipsitt,¹² Preeti N. Malani,¹³ Larissa S. May,¹⁴
Gregory J. Moran,¹⁵ Melinda M. Neuhouser,¹⁶ Jason G. Newland,¹⁷ Christopher A. Oka,¹⁸ Matthew H. Samore,¹⁹ Susan K. Seo,²⁰ and Karita K. Trivedi²¹



Requiring ASPs for Hospitals and Critical Access Hospitals (CAHs)

- ◆ In September of 2019, CMS, after close collaboration with CDC, published a final rule revising a number of the CoP requirements for all Medicare and Medicaid-participating hospitals and CAHs in an effort to update those requirements that do not fully conform to current standards of practice.
- ◆ The rule specifically updates the current requirements for hospitals to have active and hospital-wide infection prevention and control programs for surveillance, prevention, and control of healthcare-associated and other infections (and establishes new requirements for CAHs to have the same).
- ◆ Most significantly, this rule also establishes new requirements for hospitals and CAHs to now have active and facility-wide ASPs to help reduce inappropriate antibiotic use and antimicrobial resistance.
- ◆ These CoPs also require hospitals and CAHs to designate qualified leaders in these facilities to guide and oversee these efforts.
- ◆ These new CoP requirements for hospitals and CAHs must be implemented by March 30, 2020.



Strength of Rec	Strategies
Strong	<ul style="list-style-type: none"> Preauthorization/restriction Prospective audit & feedback CDI-focused intervention PK monitoring (AG) IV/PO switch Duration-focused intervention
Weak	<ul style="list-style-type: none"> Facility-specific guidelines Syndrome-specific intervention Time-out/Auto Stop Computerized Decision Support PK monitoring (Vanco) Alternate dosing for Beta Lactams Penicillin allergy assessments Stratified antibiograms Cascaded reporting of susceptibilities Rapid diagnostics: virus, blood culture Serial procalcitonin in ICU sepsis Fungal markers in Hem malignancy Febrile Neutropenia guidelines Antifungals in immunocompromised DOT>DDD AU data
Good Clinical Practice	<ul style="list-style-type: none"> Cost > purchasing data Choose clinical outcome metrics wisely Promote AS in SNFs, NICUs, terminally ill
Rec Against	<ul style="list-style-type: none"> Antibiotic Cycling Didactic education alone

“Action” for inpatient ASPs

LOTS of potential AS strategies suggested in Guidelines

Must be tailored to institutional need and priorities

AVOID: overtaxed ASP personnel

CID 2016;62(10):e51–e77

CDC “Priorities for Core Elements Implementation”








<https://www.cdc.gov/antibiotic-use/core-elements/hospital/priorities.html>



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

Table. The Core Elements of Hospital Antibiotic Stewardship Programs and the Priorities for Hospital Core Element Implementation.

Hospitals that have implemented the Hospital Core Elements of Antibiotic Stewardship can implement the Priorities for Hospital Core Element Implementation to further enhance their stewardship program.

Hospital Core Elements	Priorities for Hospital Core Element Implementation
Hospital Leadership Commitment	
 Dedicate necessary human, financial, and information technology resources.	Antibiotic stewardship physician and/or pharmacist leader(s) have antibiotic stewardship responsibilities in their contract, job description, or performance review.
Accountability	
 Appoint a leader or co-leaders, such as a physician and pharmacist, responsible for program management and outcomes.	Antibiotic stewardship program is co-led by a physician and pharmacist.*
Pharmacy/Stewardship Expertise	
 Appoint a pharmacist, ideally as the co-leader of the stewardship program, to help lead implementation efforts to improve antibiotic use.	Antibiotic stewardship physician and/or pharmacist leader(s) have completed infectious diseases specialty training, a certificate program, or other training on antibiotic stewardship.
Action	
 Implement interventions, such as prospective audit and feedback or preauthorization, to improve antibiotic use.	Antibiotic stewardship program has facility-specific treatment recommendations for common clinical condition(s) and performs prospective audit/feedback or preauthorization.
Tracking	
 Monitor antibiotic prescribing, impact of interventions, and other important outcomes, like <i>C. difficile</i> infections and resistance patterns.	Hospital submits antibiotic use data to the NHSN Antimicrobial Use Option.
Reporting	
 Regularly report information on antibiotic use and resistance to prescribers, pharmacists, nurses, and hospital leadership.	Antibiotic use reports are provided at least annually to target feedback to prescribers. In addition, the antibiotic stewardship program monitors adherence to facility-specific treatment recommendations for at least one common clinical condition.
Education	
 Educate prescribers, pharmacists, nurses, and patients about adverse reactions from antibiotics, antibiotic resistance, and optimal prescribing.	No implementation priority identified.

* For critical access hospitals (CAHs), this criterion can be met if the hospital has a physician leader with a pharmacist involved in stewardship (recognizing that some CAHs do not have pharmacists on staff, so co-leadership is not possible).

Priority “Actions” for Inpatient Stewardship

Preauthorization/restriction (before prescribing)

- Can be time/personnel intensive
- Must think through unintended consequences and process snafus
- Not for all hospitals – local culture plays a role
- Best if for targeted agents (not every antibiotic order...)

Post-prescription audit and feedback (after prescribing)

- Front-line stewardship “experts” actively review patients on antibiotics and give feedback to prescribers 1:1
- Time intensive, but effective
- Better for personal relationships
- Need ID “back up” for tough cases

“Handshake”
Stewardship
or
Stewardship Rounds

Face to face is better than
phone/pager/zoom.

CID 2016;62(10):e51–e77

Hurst A et al. PIDJ 2016;35(10):1104-10


Seidelman. CID 2022; 74(11):1986-1992

iVENTs


“The Grind”



Duke Center for Antimicrobial Stewardship and Infection Prevention



1. Antibiotic streamlining/de-escalation (35%)
2. Dose/Drug (25%)
3. Duration/Discontinuation (17%)
4. Allergy assessment (9%)
5. ID consult rec (5%)
6. IV/PO switch (3%)



Priority for Inpatient Stewardship

Facility-specific treatment recommendations for common clinical condition(s)

AMERICAN THORACIC SOCIETY DOCUMENTS

Diagnosis and Treatment of Adults with Community-acquired Pneumonia

An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

8 Joshua P. Metlay*, Grant W. Waterer*, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, Nathan C. Dean, Michael J. Fine, Scott A. Flanders, Marie R. Griffin, Mark L. Metersky, Daniel M. Musher, Marcos I. Restrepo, and Cynthia G. Whitney; on behalf of the American Thoracic Society and Infectious Diseases Society of America

THIS OFFICIAL CLINICAL PRACTICE GUIDELINE WAS APPROVED BY THE AMERICAN THORACIC SOCIETY MAY 2019 AND THE INFECTIOUS DISEASES SOCIETY OF AMERICA AUGUST 2019

Local Patient Population(s)
Local Formulary
Local antibiogram

Typically requires pharmacy + physician input, approved by hospital or system committee

Dissemination
Education
Integration into ordersets/pathways

****Assessment of Adherence (2023)**

“Tracking” Antibiotic Use

NHSN AU Option for acute care hospitals


- ONLY uses electronic data from EHRs (no manual surveillance and no subjective components)

Rate: Days of therapy (DOT) per 1,000 days present

- DOT = calendar days of treatment regardless of number of doses
- Separate drugs counted separately
- Denominator is DIFFERENT than patient days

Data is stratified by Agent, Route, Unit location

Benchmark: Standardized Antimicrobial Administration Ratio (SAAR)



REVISED
TJC
Inpatient
Stewardship
Standards:
Jan 2023

MM.09.01.01



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

Standards related to measurement of AU:

- 15. The antibiotic stewardship program **documents the evidence-based use of antibiotics** in all departments and services of the hospital.
- 16. The antibiotic stewardship program monitors the hospital's antibiotic use by analyzing data on **days of therapy per 1000 days present or 1000 patient days**, or by reporting antibiotic use data to the National Healthcare Safety Network's Antimicrobial Use Option of the Antimicrobial Use and Resistance Module.
- ...
- 19. The antibiotic stewardship program **evaluates adherence** (including antibiotic selection and duration of therapy, where applicable) **to at least one of the evidence-based guidelines** the hospital implements.
 - Note 1: The hospital may measure adherence at the group level (that is, departmental, unit, clinician subgroup) or at the individual prescriber level.
 - Note 2: The hospital may obtain adherence data for a sample of patients from relevant clinical areas by analyzing electronic health records or by conducting chart reviews.

Benchmarking AU between Hospitals

What you want to measure:

- Prescribing practices and decision-making


What you get:

- Tonnage or measure of abx exposure – not “appropriate” abx

Problems:

- Case mix
- Hospital size
- Clinical service lines (e.g. surgical specialties, types of ICUs, moms/babies)
- Assume more = bad (not always true clinically)

Should be viewed as a starting point for further investigation and explanation.



NHSN Standardized Antibiotic Administration Ratio (SAAR)

Standardized Antibiotic Administration Ratio: Observed/Expected based on NHSN baseline + limited risk adjustment with information from annual survey

- Heavily stratified: Pediatric (8), NICU (7), and Adult (7) agent groups; Pediatric (5), NICU (3), and Adult (8) NHSN unit types. No benchmarks for highly specialized units.

Baseline 2017

- Most current SAAR Targets are pooled mean + percentiles reported in annual report (2021)

<https://www.cdc.gov/nhsn/datastat/aur-reports.html>

<https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/au-saar-guide-508.pdf>

Broad spectrum antibacterial agents predominantly used for hospital-onset infections used in adult SAAR wards

Facility Org ID	SAAR Type 2017 Baseline	Location	Summary Year/Month	CDC Location	Antimicrobial Days	Predicted Antimicrobial Days	Days Present	SAAR	SAAR p-value	95% Confidence Interval	SAAR Percentile
10009	Adult_BSHO_Ward_2017	MEDSURG64	2022M01	IN:ACUTE:WARD:MS	45	36.819	320	1.222	0.1852	0.902, 1.621	64



Duke Center for
Antimicrobial Stewardship
and Infection Prevention

Antibiotic Use And Resistance Reporting Is *Now Required* for Acute Care Hospitals

The requirement was in the 2023 Inpatient Prospective Payment System rule from CMS. This is a huge, annual rule that guides how hospitals get paid.

The requirement is under the Promoting Interoperability program standard “Public Health and Clinical Data Exchange Objective”

<https://www.federalregister.gov/documents/2022/08/10/2022-16472/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the#h-623>

Not only AU Option, but also the NHSN AR module

- Hospitals that don't participate lose their incentive (\$\$\$) by Jan 2024.

Page 49335

Slide: Arjun Srinivasan

Measuring “Appropriate” or “Optimal” antimicrobial use in the Inpatient Setting

Will generally introduce subjectivity and require individual case review by a trained individual

More focused to syndrome and/or drug

- “MUE” + adherence with local guidelines

Typically sampled prevalence or retrospective study, but can be prospective and integrated into intervention delivery

Big time personnel effort

		If endorsed guidelines are present	If endorsed guidelines are absent
Appropriate	1 Optimal ¹	Antimicrobial prescription follows either the Therapeutic Guidelines ² or endorsed local guidelines <i>optimally</i> , including antimicrobial choice, dosage, route and duration ³	The antimicrobial prescription has been reviewed and endorsed by an infectious diseases clinician or a clinical microbiologist OR The prescribed antimicrobial will cover the likely causative or cultured pathogens <i>and</i> there is not a narrower spectrum or more appropriate antimicrobial choice, dosage, route or duration ³ available
	2 Adequate	Antimicrobial prescription does not optimally follow the Therapeutic Guidelines ² or endorsed local guidelines, including antimicrobial choice, dosage, route or duration ³ , however, is a <i>reasonable</i> alternative choice for the likely causative or cultured pathogens OR For surgical prophylaxis, as above <i>and</i> duration ³ is less than 24 hours	Antimicrobial prescription including antimicrobial choice, dosage, route and duration ³ is not the most optimal, however, is a <i>reasonable</i> alternative choice for the likely causative or cultured pathogens OR For surgical prophylaxis, as above <i>and</i> duration ³ is less than 24 hours
Inappropriate	3 Suboptimal	There may be a mild or non-life-threatening allergy mismatch OR Antimicrobial prescription including antimicrobial choice, dosage, route and duration ³ , is an <i>unreasonable</i> choice for the likely causative or cultured pathogens, including: <ul style="list-style-type: none"> • spectrum excessively broad, unnecessary overlap in spectrum of activity, dosage excessively high or duration excessively long • failure to appropriately de-escalate with microbiological results 	
	4 Inadequate	Antimicrobial prescription including antimicrobial choice, dosage, route or duration ³ is <i>unlikely</i> to treat the likely causative or cultured pathogens OR The documented or presumed indication does not require <i>any</i> antimicrobial treatment OR There may be a severe or possibly life-threatening allergy mismatch, or the potential risk of toxicity due to drug interaction OR For surgical prophylaxis, the duration ³ is greater than 24 hours (except where local guidelines endorse this)	
	5 Not assessable	The indication is not documented and unable to be determined from the notes OR The notes are not comprehensive enough to assess appropriateness OR The patient is too complex, due to multiple co-morbidities, allergies or microbiology results, etc.	

¹ Taking into account acceptable changes due to the patient's weight, allergy status, renal or hepatic function, or relevant drug interactions (if this information is available)

² Antibiotic Expert Group. Therapeutic Guidelines: Antibiotic. Version 16 (2019), or online version

³ Duration should only be assessed if the guidelines state a recommended duration and the antimicrobial has already been dispensed for longer than this, or if there is a clear planned 'end date' documented

CMS: ASP required in Long-term Care

CMS Requirement for Long-term Care ASPs

Barriers to Implementation of AS in LTC:

Knowledge/Evidence

Expertise

Different stakeholders + processes of care than acute care

Personnel and turnover

Resources for LTC Stewardship



ELSEVIER

JAMDA

journal homepage: www.jamda.com

Special Article

Template for an Antibiotic Stewardship Policy for Post-Acute and Long-Term Care Settings

Robin L.P. Jump MD, PhD^{a,b,*}, Swati Gaur MD, MBA, CMD^c, Morgan J. Katz MD^d, Christopher J. Crnich MD, PhD^{e,f}, Ghinwa Dumyati MD^g, Muhammad S. Ashraf MBBS^h, Elizabeth Frentzel MPHⁱ, Steven J. Schweon RN, MPH, MSN, CIC, HEM^j, Philip Sloane MD, MPH^k, David Nace MD, MPH, CMD^l on behalf of the Infection Advisory Committee for AMDA—The Society of Post-Acute and Long-Term Care Medicine

CDC Core Elements

AHRQ Guide

CMS Standard Interpretive Guidance



Duke Center for Antimicrobial Stewardship and Infection Prevention

Table 1
Resources for Antibiotic Stewardship in LTC

Category	Institution	Resource (type of link)
General Antibiotic Stewardship Principles	CDC ²	The Core Elements of Antibiotic Stewardship for Nursing Homes (website) Core Elements of Antibiotic Stewardship for Nursing Homes (pdf) Checklist for the Core Elements of Antibiotic Stewardship for Nursing Homes (pdf) Nursing Home Antimicrobial Stewardship Guide (website) Do Bugs Need Drugs? (website) Rochester Nursing Home Collaborative (website)
	AHRQ	Minnesota Antimicrobial Stewardship Program Toolkit for Long-term Care Facilities (website) Antimicrobial Stewardship in Long-Term Care (pdf) Evaluation & Treatment –UTI in Elderly (website) Promoting Wise Antibiotic Use in Nursing Homes (pdf)
	AHS and BC CDC	Policy and Practice Actions to Improve Antibiotic Use (pdf)
	Rochester Patient Safety <i>C difficile</i> Prevention Collaborative	Leading Antibiotic Stewardship in Nursing Homes (pdf) Creating a Culture to Improve Antibiotic Use in Nursing Homes (pdf) Starting an Antimicrobial Stewardship Program (website) Monitor and Sustain Stewardship (website)
	Minnesota Department of Health	Action Steps and Strategies for Implementing Antimicrobial Stewardship in Long-term Care Facilities (pdf) Antimicrobial Stewardship Gap Analysis Tool (pdf) The Core Elements of Antibiotic Stewardship with CMS and QAPI Updates (pdf) Common Suspected Infections: Communication and Decision Making for Four Infections (website) Suspected UTI SBAR Toolkit (website) Minimum Criteria for Common Infections Toolkit (website) Protocol for Three Common Infections (word document ; also included as Appendix 2) Managing Common Infections in Older Adults (pdf) Guidelines for Treatment of Urinary Tract Infections (pdf) Minimum Criteria for Initiation of Antibiotics in Long-Term Care Residents (pdf) ABCs for Diagnosing Urinary Tract Infection in Long Term Care (pdf) Measures of Antibiotic Prescribing, Use and Outcomes (pdf) Working With Your Lab to Improve Antibiotic Prescribing (website) Using Nursing Homes Antibigrams to Choose the Right Antibiotic (website) Antibiotic Tracking Worksheet (excel file) Antibiotic Tracking Sheet Instructions for Use (word document) Antibiotic Order Sheet Template (pdf) Antimicrobial Use Assessment for Long-term Care Facilities (pdf) About Antibigrams (pdf) WHONET Collaborating Centre for Surveillance of Antimicrobial Resistance (Website) What to Ask Your Healthcare Provider about Antibiotics (pdf) What You Need to Know About Antibiotics in a Nursing Home (pdf) Toolkit to Education and Engage Residents and Family Members (website) Be Smart About Antibiotics (pdf) Talking With Residents (pdf) Talking With Residents' Family Members (pdf) Resident Information Sheet: Antibiotic-Resistant Bacteria(pdf) AMDA Choosing Wisely List (pdf) AGS Choosing Wisely List (website with pdfs) AGS treatments for UTIs in older people – When you need them and when you don't (website with pdfs) FAQ for Families, Guardians and Health Care Aides-UTI in LTCF (pdf) FAQ for Families, Guardians and Health Care Aides-NHAP in LTCF (pdf) Antibiotics for Urinary Tract Infections in Older Adults (pdf) Asymptomatic Bacteriuria Family Letter Template (pdf) Why Not Antibiotics? (pdf)
Policy and Implementation	Massachusetts Coalition University of North Carolina	
	CDC	
Antibiotic Use Protocols	AHRQ	
	Minnesota Department of Health	
Measuring and Monitoring Antibiotic Use	New York Department of Health	
	AHRQ	
Family and Resident Education	Rochester Patient Safety <i>C difficile</i> Prevention Collaborative	
	Minnesota Department of Health	
	World Health Organization	
ABIM	CDC	
	AHRQ	
	ABIM	
AHS and BC CDC	AHRQ	
	AHS and BC CDC	
	Rochester Patient Safety <i>C difficile</i> Prevention Collaborative	
University of North Carolina	University of North Carolina	
	University of North Carolina	

ABIM, American Board of Internal Medicine; AGS, American Geriatrics Society; AHRQ, Agency for Healthcare Research and Quality; AHS, Alberta Health Services; BC CDC, British Columbia Center for Disease Control; CDC, Centers for Disease Control and Prevention; UTI, urinary tract infection.

Examples of Stewardship “Action” in LTC

Antibiotic use protocols – “Minimum Criteria” for Abx starts

Test/diagnostic stewardship

- UA/culture
- *C. difficile*

Durations/length of therapy and guides for common infection

- UTI
- Pneumonia
- Cellulitis

“Active monitoring” as an alternative to empiric antibiotics in patients who have a clinically undifferentiated problem (e.g. “not at baseline”)

Example: Antibiotic Use Protocol

Target: nursing assessment

Identifies “red flag” symptoms

Includes “notes” that identify key areas for baseline knowledge

Provides next steps alternative (other than an antibiotic)

Minimum Criteria for Initiating Antibiotics for a Skin and Soft Tissue Infection

Initiate antibiotics if the following criteria are met:

- New or increasing purulent drainage at a wound, skin, or soft-tissue site

OR

- At least **two** of the following:
 - Fever (temperature > 100°F [37.9°C] or two repeated temperatures of 99°F [37°C]), or
 - Redness, or
 - Tenderness, or
 - Warmth, or
 - Swelling that is new or increasing at the affected site

Notes:

1. For residents that regularly run a lower temperature, use a temperature of 2°F (1°C) above the baseline as a definition of a fever.
2. Herpes zoster is a virus and therefore does not require antibiotics but appropriate antivirals.
3. Odor is not a standalone criterion for treatment with antibiotics
4. Deeper infections such as bursitis may present with similar signs/symptoms.
5. Underlying osteomyelitis should be considered when managing a resident with an infected diabetic or decubitus ulcer.
6. Thromboembolic disease should be considered when a resident presents with an erythematous or swollen leg.
7. These criteria do not apply to residents with burns.
8. Gout can at times be mistaken for cellulitis or vice versa.

If none of the minimum criteria are met, consider initiating the following:

- Assess vital signs, including temp, every _____ hours for _____ hours; and/or
- Notify Physician/NP/PA if symptoms worsen or if unresolved in _____ hours.

Regardless of whether the minimum criteria are met or not, consider initiating the following:

- For discomfort or prior to cleaning/dressing changes, consider using acetaminophen or other pain relievers as needed.

AHRQ Toolkit: “Minimum Criteria for Common Infections”

Active Monitoring

This is an active process

More frequent vital signs

Oral hydration

Assess for pain, changes in medicine, other reasons like a bad night's sleep

(or disagreement with a loved one)



Duke Center for
Antimicrobial Stewardship
and Infection Prevention


Order Set

- Obtain vital signs (BP, Pulse, Resp Rate, Temp, Pulse Ox) every ____ hours for ____ days.
- Record fluid intake each shift for ____ days.
- Notify physician if fluid intake is less than _____ cc daily.
- Offer resident ____ ounces of water / juice every ____ hours.
- Notify physician, NP, or PA if condition worsens, or if no improvement in ____ hours.
- Obtain the following blood work _____ .
- Consult pharmacist to review medication regimen.
- Contact the physician, NP, PA with an update on the resident's condition on _____.

Nace *et al.*, JAMDA 2014;15:133-139

Potential Policies & Procedures: UTI

- Concerns about stinky or cloudy urine should lead to increased hydration and perhaps, watchful waiting/careful observation.
- Automatic review of all medication changes by outside providers.
- Send residents to the Emergency Room with a note clearly stating what you are (and are not) worried about.




Duke Center for
Antimicrobial Research
and Infection Control

NIAID
Public Health Image

Potential Policies & Procedures: UTI

- Clear criteria for collecting a urine sample
- Documented protocol for proper sample collection and handling
- Communication tools when nurses call a covering provider
- Proactively talk to residents and their family members—on admission and during change of status



Duke Center for
Antimicrobial Research
and Infection Control

NIAID
Public Health Image

Resources for Outpatient Stewardship

Outpatient Standard for TJC (Jan 2020)

4 “Core Elements”

Type of outpatient practice setting is highly varied

- Adult/pediatric
- Specialty clinics
- Retail clinics
- Urgent Care

https://www.cdc.gov/antibiotic-use/community/pdfs/16_268900-A_CoreElementsOutpatient_508.pdf



Clinician Checklist for Core Elements of Outpatient Antibiotic Stewardship

CDC recommends that outpatient clinicians take steps to implement antibiotic stewardship activities. Use this checklist as a baseline assessment of policies and practices that are in place. Then use the checklist to review progress in expanding stewardship activities on a regular basis (e.g., annually).

COMMITMENT

1. Can you demonstrate dedication to and accountability for optimizing antibiotic prescribing and patient safety related to antibiotics? Yes No

If yes, indicate which of the following are in place (select all that apply)

- Write and display public commitments in support of antibiotic stewardship.

ACTION

2. Have you implemented at least one practice to improve antibiotic prescribing? Yes No

If yes, indicate which practices which you use. (Select all that apply.)

- Use evidence-based diagnostic criteria and treatment recommendations.
 Use delayed prescribing practices or watchful waiting, when appropriate.

TRACKING AND REPORTING

3. Do you monitor at least one aspect of antibiotic prescribing? Yes No

If yes, indicate which of the following are being tracked. (Select all that apply.)

- Self-evaluate antibiotic prescribing practices.
 Participate in continuing medical education and quality improvement activities to track and improve antibiotic prescribing.

EDUCATION AND EXPERTISE

4. Do you provide education to patients and seek out continuing education on antibiotic prescribing? Yes No

If yes, indicate how you provide antibiotic stewardship education. (Select all that apply.)

- Use effective communications strategies to educate patients about when antibiotics are and are not needed.
 Educate about the potential harms of antibiotic treatment.
 Provide patient education materials

“Action” in Outpatient Stewardship

Most literature in Primary or Urgent Care

Peer comparison + data feedback

- Most commonly done for upper respiratory infection
- Identify diagnoses (e.g. viral URI) for which antibiotics should not be given. Benchmark % given abx with peers
 - HEDIS measures (primary care and pediatrics)

Suggested alternatives

Accountable justification

“Nudge” letter/poster

Education combined with the above

We want to give you some important information about antibiotics.

Antibiotics, like penicillin, fight infections due to bacteria that can cause some serious illnesses. But these medicines can cause side effects like skin rashes, diarrhea, or yeast infections. If your symptoms are from a virus and not from bacteria, you won't get better with an antibiotic, and you could still get these bad side effects.

Antibiotics also make bacteria more resistant to them. This can make future infections harder to treat. This means that antibiotics might not work when you really need them. Because of this, it is important that you only use an antibiotic when it is necessary to treat your illness.

How can you help? Carefully follow your doctor's instructions. He or she will tell you if you should or should not take antibiotics.

When you have a cough, sore throat, or other illness, your doctor will help you select the best possible treatments. If an antibiotic would do more harm than good, your doctor will explain this to you, and may offer other treatments that are better for you.

Your health is very important to us. As your doctors, we promise to treat your illness in the best way possible. We are also dedicated to avoid prescribing antibiotics when they are likely to do more harm than good.

If you have any questions, please feel free to ask your doctor, nurse, or pharmacist.

Gerber. JAMA 2013;309(22):2345-2352
Meeker. JAMA 2016; 315(6):562-570
Meeker. JAMA Intern Med. 2014;174(3):425-431.

HOT in Stewardship RN



Diagnostic Stewardship

- SHEA Task Force for Diagnostic Stewardship (e.g. Urine testing, C. difficile, Blood cultures)
- Fabre ICHE 2023 44(2), 178-185. doi:10.1017/ice.2023.5

Transitions of Care, including antibiotic durations at discharge

- Mercuro. JAMA Network Open 2022 5(5):e2211331. doi: 10.1001/jamanetworkopen.2022.11331

Outpatient parenteral antibiotic therapy (OPAT) to Complex Outpatient Antibiotic Therapy (COPAT)

- JAC 74(8):2119-2121

Management bundles (e.g. Gram negative BSI)

- Appropriate risk assessment/stratification, use of ID consultation
- Oral transition, short durations, follow up blood culture guidance
- Heil Open Forum Infect Dis. 2021 8(10): ofab434.

Diversity, Equity, and Inclusion in antibiotic prescribing

A case, continued.

86F with history of dementia, diabetes, and poor functional status presents from SNF with confusion, fever.

Day 3: Remains on vancomycin and zosyn. Progress note still says “sepsis.” BCx negative. Awake/interactive.

Clinical pharmacist reviews the patient for vancomycin dosing, sees urine +E. coli susceptible to multiple oral and intravenous agents.

Contacts the provider.

Clinical Discussion

1

Does the patient have an infection that requires antibiotics?

2

Have I ordered appropriate cultures before starting antibiotics?
What empirical antibiotic therapy should I initiate?

3

A day or more has passed.
Can I stop antibiotics?
Can I narrow therapy?
Can I change from IV to oral therapy?

4

What duration of antibiotic therapy is needed for this patient's diagnosis?

Summary

Antibiotics are life-saving medicines that are often misused.

Antimicrobial decision-making is complex.

Optimized antimicrobial use through antimicrobial stewardship protects patients from unintended consequences.

Antimicrobial use affects individuals AND populations. Healthcare exposed populations are the most at risk.

Antimicrobial Stewardship Programs are required in US healthcare facilities and a key component of infection prevention.



THANK YOU!

Rebekah.Moehring@duke.edu

Antibiotics with Gram Positive (+) Activity

<i>S. aureus</i>	MRSA	VRE	<i>E. faecalis</i>
Nafcillin/Oxacillin			Ampicillin
Ampicillin/Sulbactam, Piperacillin/Tazobactam			Ampicillin/Sulbactam, Piperacillin/Tazobactam
Cephalosporins	Ceftaroline (only)		
Carbapenems			
(Fluoroquinolones)			
Vancomycin	Vancomycin		Vancomycin
Clindamycin	Clindamycin +/-		
Linezolid	Linezolid	Linezolid	Linezolid
Daptomycin	Daptomycin	Daptomycin	Daptomycin
Telavancin	Telavancin		
TMP-SMX	TMP-SMX		
Dalvabancin, Oritavancin	Dalvabancin, Oritavancin		



Antibiotics with Gram Negative (-) Activity

<i>E. coli</i>	<i>K. pneumoniae</i>	<i>Enterobacter</i>	<i>P. aeruginosa</i>
(Ampicillin)			
(Amp/sulb)	(Amp/sulb)		
Pip/Tazo	Pip/Tazo	Pip/Tazo	Pip/Tazo
Cephalosporins	Cephalosporins	3 rd , 4 th , 5 th gen.	Ceftaz/Cefepime
Carbapenems	Carbapenems	Carbapenems	Imip, Mero, Dori
Aztreonam	Aztreonam	Aztreonam	Aztreonam
Aminoglycosides	Aminoglycosides	Aminoglycosides	Amino-glycosides
Fluoroquinolone	Fluoroquinolone	Fluoroquinolone	Cipro and Levo
Trimeth/Sulf	Trimeth/Sulf	Trimeth/Sulf	



Antibiotic use assoc. with *CDI* risk – even in patients who don't get Abx!


46-month, single center retrospective study

255 of 34,298 patients developed CDI
(Incidence rate, 5.95 per 10,000 ptd)

Each 10% increase in ward-level antibiotic exposure was associated with a 2.1 per 10,000 increase in CDI

After adjustment for patient-level RFs, effect persisted: Relative risk, 1.34 (1.16-1.57) per 10% increase in days of therapy

Figure 2. Ward *Clostridium difficile* Infection (CDI) Incidence and Antibiotic Use Across Hospital Wards and Among Patients With and Without Direct Antibiotic Exposure



Each pair of numbered symbols represents the incidence of *C difficile* infection among the subset of patients who received antibiotics (diamonds) and those who did not (circles) within a given ward. For correspondence of ward identifiers, see Table 2. DOTs indicates days of therapy.